FY2025 · ended Dec 31, 2025 · Revenue $824.50M, -1.6% YoY · Filed Feb 24, 2026
Myriad Genetics, Inc. (MYGN) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $824.5 million and a net loss of $365.9 million. As of Jun 30, 2026 it held $115.2 million in cash and investments and $210.5 million in total debt.
Revenue (TTM)
$806.60M
-3.2% vs year-ago TTM
Net income (TTM)
$-112.60M
+71.5% vs year-ago TTM
Operating cash flow (TTM)
$7.70M
+134.1% vs year-ago TTM
Free cash flow
$-151.60M
-25366.7% vs prior year
EPS (TTM)
$-1.20
+72.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
93.51M
+2.4% vs prior year
Net cash
$-95.30M
as of Jun 30, 2026
Operating margin
-12.2%
FY 2026
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- MYGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Accelerated filer
- SEC CIK
- 899923
- Former names
- MYRIAD GENETICS INC (until Nov 4, 2026)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Alpha Teknova, Inc. TKNO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $824.5M | $837.6M | $753.2M | $678.4M | $690.6M |
| Operating income | -$387.2M | -$123.5M | -$257.4M | -$140.6M | -$190.5M |
| Net income | -$365.9M | -$127.3M | -$263.3M | -$112.0M | -$27.2M |
| Diluted EPS | -$3.95 | -$1.41 | -$3.18 | -$1.39 | -$0.35 |
| Operating cash flow | $1.8M | -$8.7M | -$110.9M | -$106.3M | $18.6M |
| Free cash flow | — | — | — | -$151.6M | $600,000 |
| Total assets | $706.6M | $1.0B | $1.1B | $1.2B | $1.3B |
| Total liabilities | $338.6M | $326.5M | $363.3M | $312.9M | $352.9M |
| Stockholders' equity | $368.0M | $701.1M | $783.2M | $885.8M | $967.8M |
| Cash and investments | $149.6M | $102.4M | $140.9M | $169.7M | $397.8M |
| Total debt | $209.8M | $140.3M | $152.1M | $145.0M | $92.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 20, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 9, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 16, 2026 | Sep 15, 2026 |
| 10-Q | Quarterly report | Jul 31, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
All 1001 Myriad Genetics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.